Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.

Journal of viral hepatitis - 1 Apr 2014

Wyles D L, Gutierrez J A

Abstract excerpt

The treatment for patients infected with hepatitis C virus (HCV) genotype 1 has undergone major changes with the availability of direct-acting antivirals. Triple therapy, containing telaprevir or boceprevir, first-wave NS3 protease inhibitors, in combination with peginterferon and ribavirin, improved rates of sustained virologic response compared with peginterferon and ribavirin alone in patients with HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 24597691
DOI: 10.1111/jvh.12230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.PMID 24597691Read ↗

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Semantic proximity Read ↗

The role of resistance in HCV treatment.Semantic proximity Read ↗

Hepatitis C virus resistance to the new direct-acting antiviralsSemantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Resistance mutations against HCV protease inhibitors and antiviral drug design.Semantic proximity Read ↗

Characterization of Primary Direct Acting Antiviral Drugs (DAA) Resistance Mutations in NS5A/NS5B Regions of Hepatitis C Virus with Genotype 1a and 1b from Patients with Chronic HepatitisSemantic proximity Read ↗

Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus InfectionSemantic proximity Read ↗

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.Semantic proximity Read ↗

Resistance to direct-acting antiviral agents: clinical utility and significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.